- $771.42m
- $1.01bn
- $38.47m
Annual cashflow statement for Apnimed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -111 | -128 |
| Depreciation | ||
| Non-Cash Items | 1.31 | 79.9 |
| Discontinued Operations | ||
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | -0.238 | -29.6 |
| Change in Accounts Receivable | ||
| Change in Prepaid Expenses | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Change in Other Liabilities | ||
| Cash from Operating Activities | -110 | -77.8 |
| Capital Expenditures | -0.07 | 0 |
| Purchase of Fixed Assets | ||
| Other Investing Cash Flow Items | 152 | 0 |
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Cash from Investing Activities | 152 | 0 |
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 0.051 | 51.4 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 41.8 | -26.5 |